136465-85-5

Usage

Uses

Used in Organic Synthesis:
(3S,4AS,8AS)-2-CARBOBENZYLOXY-DECAHYDRO-3-ISOQUINOLINECARBOXYLIC ACID is used as a synthetic building block for the creation of more complex organic molecules. Its unique structure and functional groups allow it to be a versatile component in the synthesis of various compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (3S,4AS,8AS)-2-CARBOBENZYLOXY-DECAHYDRO-3-ISOQUINOLINECARBOXYLIC ACID is used as an intermediate in the development of new drugs. Its specific stereochemistry and functional groups make it a valuable starting material for the synthesis of potential therapeutic agents, which could be used to treat various diseases and medical conditions.
Used in Research and Development:
(3S,4AS,8AS)-2-CARBOBENZYLOXY-DECAHYDRO-3-ISOQUINOLINECARBOXYLIC ACID is also used in research and development laboratories for studying the properties and reactivity of complex organic molecules. Its unique structure provides researchers with valuable insights into the behavior of similar compounds and can help in the design and development of new synthetic routes and methodologies.

Upstream product

• 501-53-1 benzyl chloroformate 
• 173325-14-9 (3R,4aS,8aS)-Decahydro-isoquinoline-3-carboxylic acid 
• 82717-30-4 decahydro-3-isoquinolinecarboxylic acid 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 103733-65-9 (3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Structure-Activity Study of Tripeptide Thrombin Inhibitors Using α-Alkyl Amino Acids and Other Conformationally Constrained Amino Acid Substitutions

In our continuing effort to design novel thrombin inhibitors, a series of conformationally constrained amino acids (e.g. α-alkyl, N-alkyl cyclic, etc.) were utilized in a systematic structure-activity study of the P3, P2, and P1 positions of tripeptide arginal thrombin inhibitors.Early examples of this effort include: D-MePhe-Pro-Arg-H (15), Boc-D-Phg-Pro-Arg-H (18), D-1-Tiq-Pro-Arg-H (23, D-1-Tiq = D-1,2,3,4-tetrahydroisoquinolin-1-ylcarbonyl), and Boc-D-Phe-Pro-Arg-H (25).10a,20 The current work clarifies the contribution of each residue of the tripeptide arginals toward the potent and selective inhibition of thrombin relative to that of t-PA and plasmin.The α-methylarginal modification in the P1 residue resulted in analogs 30 (D-MePhe at P3) and 32 (D-1-Tiq at P3) which had lower potency toward thrombin while exhibiting improved selectivity.Analogs modified at the P2 site were found to be very sensitive to the conformational changes induced by variations in side chain ring size with the flexible pipecolinic acid 31 being 2 orders of magnitude less potent at thrombin inhibition than the conformationally constrained azetidine analog 20.Examination of the P3 binding region indicated that α-alkylphenylglycine residues resulted in a tendency to exhibit substantional improvements in selectivity over the nonalkylated residues.Combinations of optimal P3 and P2 changes led to compounds TFA-D-Phg(αEt)-Azt-Arg-H (16), TFA-D-Phg(αMe)-Azt-Arg-H (17), Ac-D-Phg(αMe)-Azt-Arg-H (21), TFA-D-Phg(αMe)-Pro-Arg-H (27), 30, and 32, which are clearly more selective for thrombin versus plasmin than the nonconformationally constrained compounds.

Amino acid derivatives

Compounds having the formula STR1 wherein R is benzyloxycarbonyl or 2-quinolylcarbonyl, and their pharmaceutically acceptable acid addition salts inhibit proteases of viral origin and can be used as medicaments for the treatment of prophylaxis of viral in

Bicyclic α-iminocarboxylic acid compounds having hypotensive activity

What are disclosed are indole, quinoline and isoquinoline compounds of the formula STR1 in which n denotes 0 or 1, m denotes 1 or 2, but (n+m)≤2, A together with the bridgehead carbon atoms denotes a benzene or a cyclohexane ring, Y1 denotes hy